Lantern Pharma(LTRN) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates ■ Lantern is advancing three AI-guided precision-oncology drug candidates in active Phase 1 and Phase 2 clinical trials, while evaluating additional ADC-based preclinical molecules for development. ■ Preliminary patient data and clinical readouts for the Phase 2 LP-300 Harmonic™ Trial showed an 86% clinical benefit rate in the initial 7 patient lead-in cohort, and additional patients continue to be enrolled in the ...